Hanmi Science (KRX:008930) secured a contract for the supply of Daparon tablets/Daparon Duo extended-release tablets with Mexico's Laboratorios Sanfer, according to a Wednesday filing with the Korea Exchange.
The contract, valued at 65.8 billion won, is valid till Jan. 26, 2036.
Shares of Hanmi Science rose over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.